NVAX Key Stats
- Will Influenza A H7N9 Generate Opportunities For Pharma? May 21
- Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer PR Newswire May 20
- 6 Superstars For Your Biotech Portfolio: John McCamant May 10
- Novavax H7N9 VLP Influenza Vaccine Enters Animal Testing GlobeNewswire May 10
- NOVAVAX INC Files SEC form 10-Q, Quarterly Report May 9
- Novavax's CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 7
- NOVAVAX INC Files SEC form 8-K, Results of Operations and Financial Condition, F... May 7
- Novavax Earnings: Everything You Must Know Now May 7
- Novavax, Inc. (NVAX) Misses Q1 EPS by 1c Street Insider May 7
- Novavax Reports First-Quarter 2013 Financial Results GlobeNewswire May 7
NVAX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novavax is up 75.86% over the last year vs S&P 500 Total Return up 28.33%, Sinovac Biotech up 88.20%, and Biocryst Pharmaceuticals down 50.00%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for NVAX
Pro Report PDF for NVAX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download NVAX Pro Report PDF
Pro Strategies Featuring NVAX
Did Novavax make it into our Pro Portfolio Strategies?